Previous close | 133.66 |
Open | 140.62 |
Bid | 140.06 x 100 |
Ask | 140.29 x 100 |
Day's range | 139.22 - 145.00 |
52-week range | 89.04 - 148.37 |
Volume | |
Avg. volume | 880,037 |
Market cap | 14.09B |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | 56.72 |
EPS (TTM) | 2.47 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 29 Dec 1995 |
1y target est | 151.96 |
Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]